Andrew M Baschnagel1, Lindsay Williams2, Alaa Hanna1, Peter Y Chen1, Daniel J Krauss1, Barbara L Pruetz3, Jan Akervall4, George D Wilson5. 1. Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan. 2. Department of Pathology, William Beaumont Hospital, Royal Oak, Michigan. 3. Beaumont BioBank, William Beaumont Hospital, Royal Oak, Michigan. 4. Beaumont BioBank, William Beaumont Hospital, Royal Oak, Michigan; Department of Otolaryngology, William Beaumont Hospital, Royal Oak, Michigan. 5. Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan; Beaumont BioBank, William Beaumont Hospital, Royal Oak, Michigan. Electronic address: George.Wilson@Beaumont.edu.
Abstract
PURPOSE: To examine the prognostic significance of c-Met expression in relation to p16 and epidermal growth factor receptor (EGFR) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with definitive concurrent chemoradiation. METHODS AND MATERIALS: Archival tissue from 107 HNSCC patients treated with chemoradiation was retrieved, and a tissue microarray was assembled. Immunohistochemical staining of c-Met, p16, and EGFR was performed. c-Met expression was correlated with p16, EGFR, clinical characteristics, and clinical endpoints including locoregional control (LRC), distant metastasis (DM), disease-free survival (DFS), and overall survival (OS). RESULTS: Fifty-one percent of patients were positive for p16, and 53% were positive for EGFR. Both p16-negative (P≤.001) and EGFR-positive (P=.019) status predicted for worse DFS. Ninety-three percent of patients stained positive for c-Met. Patients were divided into low (0, 1, or 2+ intensity) or high (3+ intensity) c-Met expression. On univariate analysis, high c-Met expression predicted for worse LRC (hazard ratio [HR] 2.27; 95% CI, 1.08-4.77; P=.031), DM (HR 4.41; 95% CI, 1.56-12.45; P=.005), DFS (HR 3.00; 95% CI, 1.68-5.38; P<.001), and OS (HR 4.35; 95% CI, 2.13-8.88; P<.001). On multivariate analysis, after adjustment for site, T stage, smoking history, and EGFR status, only high c-Met expression (P=.011) and negative p16 status (P=.003) predicted for worse DFS. High c-Met expression was predictive of worse DFS in both EGFR-positive (P=.032) and -negative (P=.008) patients. In the p16-negative patients, those with high c-Met expression had worse DFS (P=.036) than did those with low c-Met expression. c-Met expression was not associated with any outcome in the p16-positive patients. CONCLUSIONS: c-Met is expressed in the majority of locally advanced HNSCC cases, and high c-Met expression predicts for worse clinical outcomes. High c-Met expression predicted for worse DFS in p16-negative patients but not in p16-positive patients. c-Met predicted for worse outcome regardless of EGFR status.
PURPOSE: To examine the prognostic significance of c-Met expression in relation to p16 and epidermal growth factor receptor (EGFR) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with definitive concurrent chemoradiation. METHODS AND MATERIALS: Archival tissue from 107 HNSCCpatients treated with chemoradiation was retrieved, and a tissue microarray was assembled. Immunohistochemical staining of c-Met, p16, and EGFR was performed. c-Met expression was correlated with p16, EGFR, clinical characteristics, and clinical endpoints including locoregional control (LRC), distant metastasis (DM), disease-free survival (DFS), and overall survival (OS). RESULTS: Fifty-one percent of patients were positive for p16, and 53% were positive for EGFR. Both p16-negative (P≤.001) and EGFR-positive (P=.019) status predicted for worse DFS. Ninety-three percent of patients stained positive for c-Met. Patients were divided into low (0, 1, or 2+ intensity) or high (3+ intensity) c-Met expression. On univariate analysis, high c-Met expression predicted for worse LRC (hazard ratio [HR] 2.27; 95% CI, 1.08-4.77; P=.031), DM (HR 4.41; 95% CI, 1.56-12.45; P=.005), DFS (HR 3.00; 95% CI, 1.68-5.38; P<.001), and OS (HR 4.35; 95% CI, 2.13-8.88; P<.001). On multivariate analysis, after adjustment for site, T stage, smoking history, and EGFR status, only high c-Met expression (P=.011) and negative p16 status (P=.003) predicted for worse DFS. High c-Met expression was predictive of worse DFS in both EGFR-positive (P=.032) and -negative (P=.008) patients. In the p16-negative patients, those with high c-Met expression had worse DFS (P=.036) than did those with low c-Met expression. c-Met expression was not associated with any outcome in the p16-positive patients. CONCLUSIONS:c-Met is expressed in the majority of locally advanced HNSCC cases, and high c-Met expression predicts for worse clinical outcomes. High c-Met expression predicted for worse DFS in p16-negative patients but not in p16-positive patients. c-Met predicted for worse outcome regardless of EGFR status.
Authors: Mathias Fiedler; Florian Weber; Matthias G Hautmann; Frank Haubner; Torsten E Reichert; Christoph Klingelhöffer; Stephan Schreml; Johannes K Meier; Arndt Hartmann; Tobias Ettl Journal: Clin Oral Investig Date: 2017-03-18 Impact factor: 3.573
Authors: Chad Tang; Xiaohong Wang; Hendrick Soh; Steven Seyedin; Maria Angelica Cortez; Sunil Krishnan; Erminia Massarelli; David Hong; Aung Naing; Adi Diab; Daniel Gomez; Huiping Ye; John Heymach; Ristuko Komaki; James P Allison; Padmanee Sharma; James W Welsh Journal: Cancer Immunol Res Date: 2014-09 Impact factor: 11.151
Authors: Alexandre A B A da Costa; Felipe D'Almeida Costa; Daniel Vilarim Araújo; Marcos Pedro Guedes Camandaroba; Victor Hugo Fonseca de Jesus; Audrey Oliveira; Ana Caroline Fonseca Alves; Carlos Stecca; Larissa Machado; Andrea Cruz Feraz de Oliveira; Thiago Bueno de Oliveira; Ulisses Ribaldo Nicolau; Vladmir Cláudio Cordeiro de Lima Journal: Med Oncol Date: 2018-11-26 Impact factor: 3.064
Authors: Aisha A H Al-Jamaei; Jan G A M de Visscher; Tymour Forouzanfar; Ruud H Brakenhoff; C René Leemans; Arwen Stikvoort; Behrouz Zandieh-Doulabi; Marco N Helder Journal: J Cancer Res Clin Oncol Date: 2022-09-02 Impact factor: 4.322
Authors: Vicki L Keedy; Heinz-Josef Lenz; Leonard Saltz; Jennifer G Whisenant; Jordan D Berlin; Luis H Camacho Journal: Invest New Drugs Date: 2018-01-29 Impact factor: 3.850
Authors: George D Wilson; Bryan J Thibodeau; Laura E Fortier; Barbara L Pruetz; Sandra Galoforo; Brian Marples; Andrew M Baschnagel; Jan Akervall; Jiayi Huang Journal: Stem Cells Int Date: 2016-01-06 Impact factor: 5.443